Lv11
40 积分 2025-06-28 加入
IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial
13小时前
待确认
Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China
1天前
已完结
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study
1天前
已完结
皖公网安备34019202002308
